Upexi, Inc. (NASDAQ: GRVI) Stock Competitors & Peer Comparison
See GRVI's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GRVI and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRVI | $4.95 | +7.61% | 88.9M | 26.05 | $0.19 | N/A |
| TAK | $18.71 | +1.52% | 59.5B | 13.45 | $1.39 | +3.37% |
| HLN | $9.86 | -0.50% | 43.4B | 18.39 | $0.54 | +2.01% |
| TEVA | $36.62 | -2.32% | 42.6B | 12.50 | $2.93 | N/A |
| ZTS | $76.29 | +0.16% | 32B | 11.59 | $6.58 | +2.73% |
| VTRS | $16.94 | -0.88% | 19.7B | 6.72 | $2.52 | +2.83% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.42 | -1.05% | 12.2B | 23.03 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.03 | -1.11% | 10B | 19.73 | $0.61 | +0.70% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
GRVI vs TAK Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TAK has a market cap of 59.5B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TAK trades at $18.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TAK's P/E ratio is 13.45. In terms of profitability, GRVI's ROE is -2.54%, compared to TAK's ROE of +0.02%. Regarding short-term risk, GRVI is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TAK's competition here
Haleon plc (NYSE: HLN)
GRVI vs HLN Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, HLN has a market cap of 43.4B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while HLN trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas HLN's P/E ratio is 18.39. In terms of profitability, GRVI's ROE is -2.54%, compared to HLN's ROE of +0.17%. Regarding short-term risk, GRVI is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
GRVI vs TEVA Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TEVA has a market cap of 42.6B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TEVA trades at $36.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TEVA's P/E ratio is 12.50. In terms of profitability, GRVI's ROE is -2.54%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, GRVI is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
GRVI vs ZTS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ZTS has a market cap of 32B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ZTS trades at $76.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ZTS's P/E ratio is 11.59. In terms of profitability, GRVI's ROE is -2.54%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, GRVI is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
GRVI vs VTRS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, VTRS has a market cap of 19.7B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while VTRS trades at $16.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas VTRS's P/E ratio is 6.72. In terms of profitability, GRVI's ROE is -2.54%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, GRVI is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
GRVI vs ITCI Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ITCI's P/E ratio is -180.64. In terms of profitability, GRVI's ROE is -2.54%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, GRVI is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
GRVI vs ELAN Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ELAN has a market cap of 12.2B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ELAN trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ELAN's P/E ratio is 23.03. In terms of profitability, GRVI's ROE is -2.54%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, GRVI is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
GRVI vs CTLT Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CTLT's P/E ratio is -27.84. In terms of profitability, GRVI's ROE is -2.54%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, GRVI is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
GRVI vs RDY Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, RDY has a market cap of 10B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while RDY trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas RDY's P/E ratio is 19.73. In terms of profitability, GRVI's ROE is -2.54%, compared to RDY's ROE of +0.09%. Regarding short-term risk, GRVI is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
GRVI vs ALKS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ALKS has a market cap of 7.9B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ALKS trades at $46.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ALKS's P/E ratio is 49.35. In terms of profitability, GRVI's ROE is -2.54%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, GRVI is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
GRVI vs LNTH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while LNTH trades at $100.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas LNTH's P/E ratio is 16.97. In terms of profitability, GRVI's ROE is -2.54%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, GRVI is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
GRVI vs AMRX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while AMRX trades at $17.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas AMRX's P/E ratio is 19.86. In terms of profitability, GRVI's ROE is -2.54%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, GRVI is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
GRVI vs INDV Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, INDV has a market cap of 4.3B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while INDV trades at $34.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas INDV's P/E ratio is 9.54. In terms of profitability, GRVI's ROE is -2.54%, compared to INDV's ROE of -2.16%. Regarding short-term risk, GRVI is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check INDV's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
GRVI vs RGC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, RGC has a market cap of 3.2B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while RGC trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas RGC's P/E ratio is -456.34. In terms of profitability, GRVI's ROE is -2.54%, compared to RGC's ROE of -2.32%. Regarding short-term risk, GRVI is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check RGC's competition here
Alvotech (NASDAQ: ALVOW)
GRVI vs ALVOW Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ALVOW's P/E ratio is 46.65. In terms of profitability, GRVI's ROE is -2.54%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, GRVI is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check ALVOW's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
GRVI vs SUPN Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, SUPN has a market cap of 2.6B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while SUPN trades at $43.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas SUPN's P/E ratio is 14.38. In terms of profitability, GRVI's ROE is -2.54%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, GRVI is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
GRVI vs BHC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while BHC trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas BHC's P/E ratio is 1.73. In terms of profitability, GRVI's ROE is -2.54%, compared to BHC's ROE of +0.89%. Regarding short-term risk, GRVI is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check BHC's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
GRVI vs HCM Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while HCM trades at $14.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas HCM's P/E ratio is 5.29. In terms of profitability, GRVI's ROE is -2.54%, compared to HCM's ROE of +0.01%. Regarding short-term risk, GRVI is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check HCM's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
GRVI vs DCPH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas DCPH's P/E ratio is -11.58. In terms of profitability, GRVI's ROE is -2.54%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, GRVI is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
GRVI vs AVDL Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, GRVI's ROE is -2.54%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, GRVI is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
GRVI vs TRLV Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TRLV trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TRLV's P/E ratio is -4.88. In terms of profitability, GRVI's ROE is -2.54%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, GRVI is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TRLV's competition here
Perrigo Company plc (NYSE: PRGO)
GRVI vs PRGO Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, PRGO has a market cap of 2B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while PRGO trades at $14.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas PRGO's P/E ratio is 5.71. In terms of profitability, GRVI's ROE is -2.54%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, GRVI is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check PRGO's competition here
Embecta Corp. (NASDAQ: EMBCV)
GRVI vs EMBCV Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas EMBCV's P/E ratio is N/A. In terms of profitability, GRVI's ROE is -2.54%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, GRVI is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
GRVI vs DVAX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas DVAX's P/E ratio is -41.89. In terms of profitability, GRVI's ROE is -2.54%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, GRVI is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
GRVI vs ALVO Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ALVO trades at $5.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ALVO's P/E ratio is -15.82. In terms of profitability, GRVI's ROE is -2.54%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, GRVI is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
GRVI vs ETON Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ETON trades at $59.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ETON's P/E ratio is 130.22. In terms of profitability, GRVI's ROE is -2.54%, compared to ETON's ROE of +0.40%. Regarding short-term risk, GRVI is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ETON's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
GRVI vs ANIP Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ANIP has a market cap of 1.6B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ANIP trades at $71.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ANIP's P/E ratio is 8.76. In terms of profitability, GRVI's ROE is -2.54%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, GRVI is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
GRVI vs TARO Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TARO's P/E ratio is 30.05. In terms of profitability, GRVI's ROE is -2.54%, compared to TARO's ROE of +0.03%. Regarding short-term risk, GRVI is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
GRVI vs PAHC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while PAHC trades at $38.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas PAHC's P/E ratio is 13.17. In terms of profitability, GRVI's ROE is -2.54%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, GRVI is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
GRVI vs HROW Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while HROW trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas HROW's P/E ratio is -38.65. In terms of profitability, GRVI's ROE is -2.54%, compared to HROW's ROE of -1.04%. Regarding short-term risk, GRVI is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
GRVI vs CRON Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CRON trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CRON's P/E ratio is 30.96. In terms of profitability, GRVI's ROE is -2.54%, compared to CRON's ROE of +0.06%. Regarding short-term risk, GRVI is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
GRVI vs AMPH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while AMPH trades at $23.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas AMPH's P/E ratio is 8.14. In terms of profitability, GRVI's ROE is -2.54%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, GRVI is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check AMPH's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
GRVI vs PCRX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while PCRX trades at $26.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas PCRX's P/E ratio is 10.23. In terms of profitability, GRVI's ROE is -2.54%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, GRVI is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
GRVI vs PETQ Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas PETQ's P/E ratio is 83.73. In terms of profitability, GRVI's ROE is -2.54%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, GRVI is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
GRVI vs COLL Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, COLL has a market cap of 768.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while COLL trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas COLL's P/E ratio is 2.97. In terms of profitability, GRVI's ROE is -2.54%, compared to COLL's ROE of +0.16%. Regarding short-term risk, GRVI is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
GRVI vs IRWD Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, IRWD has a market cap of 706.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while IRWD trades at $4.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas IRWD's P/E ratio is 5.50. In terms of profitability, GRVI's ROE is -2.54%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, GRVI is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
GRVI vs EVO Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, EVO has a market cap of 675M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while EVO trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas EVO's P/E ratio is -2.68. In terms of profitability, GRVI's ROE is -2.54%, compared to EVO's ROE of -0.27%. Regarding short-term risk, GRVI is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
GRVI vs AQST Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, AQST has a market cap of 671.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while AQST trades at $5.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas AQST's P/E ratio is -8.23. In terms of profitability, GRVI's ROE is -2.54%, compared to AQST's ROE of +2.44%. Regarding short-term risk, GRVI is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check AQST's competition here
Glass House Brands Inc (NYSE: GLAS)
GRVI vs GLAS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, GLAS has a market cap of 662.8M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while GLAS trades at $8.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas GLAS's P/E ratio is -15.30. In terms of profitability, GRVI's ROE is -2.54%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, GRVI is more volatile compared to GLAS. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check GLAS's competition here
Evolus, Inc. (NASDAQ: EOLS)
GRVI vs EOLS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, EOLS has a market cap of 596M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while EOLS trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas EOLS's P/E ratio is -28.66. In terms of profitability, GRVI's ROE is -2.54%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, GRVI is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
GRVI vs BDSI Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas BDSI's P/E ratio is 6.82. In terms of profitability, GRVI's ROE is -2.54%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, GRVI is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
GRVI vs TLRY Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TLRY has a market cap of 506.6M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TLRY trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TLRY's P/E ratio is -4.18. In terms of profitability, GRVI's ROE is -2.54%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, GRVI is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
GRVI vs KMDA Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, KMDA has a market cap of 477.1M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while KMDA trades at $8.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas KMDA's P/E ratio is 21.76. In terms of profitability, GRVI's ROE is -2.54%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, GRVI is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
GRVI vs CGC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CGC has a market cap of 410.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CGC's P/E ratio is -0.59. In terms of profitability, GRVI's ROE is -2.54%, compared to CGC's ROE of -0.33%. Regarding short-term risk, GRVI is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
GRVI vs TKNO Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TKNO has a market cap of 388.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TKNO trades at $7.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TKNO's P/E ratio is -23.35. In terms of profitability, GRVI's ROE is -2.54%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, GRVI is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
GRVI vs EBS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, EBS has a market cap of 322M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while EBS trades at $6.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas EBS's P/E ratio is 4.33. In terms of profitability, GRVI's ROE is -2.54%, compared to EBS's ROE of -0.36%. Regarding short-term risk, GRVI is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
GRVI vs ALIM Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ALIM's P/E ratio is 5.28. In terms of profitability, GRVI's ROE is -2.54%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, GRVI is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
GRVI vs LNDC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas LNDC's P/E ratio is -4.04. In terms of profitability, GRVI's ROE is -2.54%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, GRVI is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check LNDC's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
GRVI vs CRDL Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CRDL has a market cap of 249M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CRDL trades at $2.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CRDL's P/E ratio is -8.61. In terms of profitability, GRVI's ROE is -2.54%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, GRVI is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check CRDL's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
GRVI vs ACB Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ACB has a market cap of 241M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ACB trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ACB's P/E ratio is -7.94. In terms of profitability, GRVI's ROE is -2.54%, compared to ACB's ROE of -0.21%. Regarding short-term risk, GRVI is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ACB's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
GRVI vs SIGA Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, SIGA has a market cap of 231.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while SIGA trades at $3.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas SIGA's P/E ratio is 11.96. In terms of profitability, GRVI's ROE is -2.54%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, GRVI is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check SIGA's competition here
Shineco, Inc. (NASDAQ: TYHT)
GRVI vs TYHT Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TYHT's P/E ratio is -1.61. In terms of profitability, GRVI's ROE is -2.54%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, GRVI is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TYHT's competition here
Journey Medical Corporation (NASDAQ: DERM)
GRVI vs DERM Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, DERM has a market cap of 217.4M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while DERM trades at $7.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas DERM's P/E ratio is -21.35. In terms of profitability, GRVI's ROE is -2.54%, compared to DERM's ROE of -0.20%. Regarding short-term risk, GRVI is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check DERM's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
GRVI vs ORGO Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ORGO has a market cap of 211M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ORGO trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ORGO's P/E ratio is 54.67. In terms of profitability, GRVI's ROE is -2.54%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, GRVI is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ORGO's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
GRVI vs REPH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas REPH's P/E ratio is -8.04. In terms of profitability, GRVI's ROE is -2.54%, compared to REPH's ROE of -0.22%. Regarding short-term risk, GRVI is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
GRVI vs OGI Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, OGI has a market cap of 164.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while OGI trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas OGI's P/E ratio is 2.63. In terms of profitability, GRVI's ROE is -2.54%, compared to OGI's ROE of +0.21%. Regarding short-term risk, GRVI is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
GRVI vs LFCR Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, LFCR has a market cap of 163.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while LFCR trades at $4.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas LFCR's P/E ratio is -4.07. In terms of profitability, GRVI's ROE is -2.54%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, GRVI is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
GRVI vs THTX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas THTX's P/E ratio is -28.83. In terms of profitability, GRVI's ROE is -2.54%, compared to THTX's ROE of +0.36%. Regarding short-term risk, GRVI is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
GRVI vs ASRT Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ASRT's P/E ratio is -7.10. In terms of profitability, GRVI's ROE is -2.54%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, GRVI is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ASRT's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
GRVI vs SCTL Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas SCTL's P/E ratio is -7.86. In terms of profitability, GRVI's ROE is -2.54%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, GRVI is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
GRVI vs BGM Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, BGM has a market cap of 107.8M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas BGM's P/E ratio is -0.98. In terms of profitability, GRVI's ROE is -2.54%, compared to BGM's ROE of -0.05%. Regarding short-term risk, GRVI is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
GRVI vs PROC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas PROC's P/E ratio is 1.53. In terms of profitability, GRVI's ROE is -2.54%, compared to PROC's ROE of -2.22%. Regarding short-term risk, GRVI is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
GRVI vs CPIX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CPIX has a market cap of 101.1M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CPIX trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CPIX's P/E ratio is -16.87. In terms of profitability, GRVI's ROE is -2.54%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, GRVI is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
GRVI vs OPTN Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas OPTN's P/E ratio is -4.42. In terms of profitability, GRVI's ROE is -2.54%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, GRVI is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
GRVI vs ZOM Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ZOM's P/E ratio is -1.62. In terms of profitability, GRVI's ROE is -2.54%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, GRVI is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
GRVI vs ZYBT Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ZYBT has a market cap of 77.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ZYBT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ZYBT's P/E ratio is -7.41. In terms of profitability, GRVI's ROE is -2.54%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, GRVI is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
GRVI vs ZYNE Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, GRVI's ROE is -2.54%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, GRVI is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
GRVI vs SSIC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas SSIC's P/E ratio is 11.93. In terms of profitability, GRVI's ROE is -2.54%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, GRVI is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check SSIC's competition here
InterCure Ltd. (NASDAQ: INCR)
GRVI vs INCR Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, INCR has a market cap of 62.8M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while INCR trades at $5.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas INCR's P/E ratio is -12.23. In terms of profitability, GRVI's ROE is -2.54%, compared to INCR's ROE of -0.09%. Regarding short-term risk, GRVI is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check INCR's competition here
Talphera, Inc. (NASDAQ: TLPH)
GRVI vs TLPH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TLPH's P/E ratio is -3.87. In terms of profitability, GRVI's ROE is -2.54%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, GRVI is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
GRVI vs VLNS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas VLNS's P/E ratio is -1.03. In terms of profitability, GRVI's ROE is -2.54%, compared to VLNS's ROE of N/A. Regarding short-term risk, GRVI is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
GRVI vs DRRX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas DRRX's P/E ratio is -4.44. In terms of profitability, GRVI's ROE is -2.54%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, GRVI is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
GRVI vs JUPW Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas JUPW's P/E ratio is -2.41. In terms of profitability, GRVI's ROE is -2.54%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, GRVI is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
GRVI vs QLI Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas QLI's P/E ratio is -4.92. In terms of profitability, GRVI's ROE is -2.54%, compared to QLI's ROE of -0.16%. Regarding short-term risk, GRVI is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
GRVI vs CPHI Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CPHI has a market cap of 34.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CPHI trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CPHI's P/E ratio is -1.97. In terms of profitability, GRVI's ROE is -2.54%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, GRVI is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
GRVI vs RMTI Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, RMTI has a market cap of 31.5M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while RMTI trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas RMTI's P/E ratio is -5.96. In terms of profitability, GRVI's ROE is -2.54%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, GRVI is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
GRVI vs HEXO Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas HEXO's P/E ratio is -0.26. In terms of profitability, GRVI's ROE is -2.54%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, GRVI is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
GRVI vs TXMD Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, TXMD has a market cap of 25.9M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while TXMD trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas TXMD's P/E ratio is 114.11. In terms of profitability, GRVI's ROE is -2.54%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, GRVI is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
GRVI vs AYTU Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, AYTU has a market cap of 24.5M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while AYTU trades at $2.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas AYTU's P/E ratio is -1.19. In terms of profitability, GRVI's ROE is -2.54%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, GRVI is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
GRVI vs CYTH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CYTH's P/E ratio is -0.80. In terms of profitability, GRVI's ROE is -2.54%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, GRVI is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
GRVI vs EVOK Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas EVOK's P/E ratio is -7.97. In terms of profitability, GRVI's ROE is -2.54%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, GRVI is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
GRVI vs OPTH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, OPTH has a market cap of 15.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while OPTH trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas OPTH's P/E ratio is -17.24. In terms of profitability, GRVI's ROE is -2.54%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, GRVI is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
GRVI vs ACRX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ACRX's P/E ratio is -0.31. In terms of profitability, GRVI's ROE is -2.54%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, GRVI is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
GRVI vs CABR Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, CABR has a market cap of 11.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while CABR trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas CABR's P/E ratio is -2.29. In terms of profitability, GRVI's ROE is -2.54%, compared to CABR's ROE of -3.86%. Regarding short-term risk, GRVI is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
GRVI vs AGRX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas AGRX's P/E ratio is -0.89. In terms of profitability, GRVI's ROE is -2.54%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, GRVI is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
GRVI vs NLTX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas NLTX's P/E ratio is -0.28. In terms of profitability, GRVI's ROE is -2.54%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, GRVI is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check NLTX's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
GRVI vs GELS Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, GELS has a market cap of 7.9M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while GELS trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas GELS's P/E ratio is -1.72. In terms of profitability, GRVI's ROE is -2.54%, compared to GELS's ROE of -0.25%. Regarding short-term risk, GRVI is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check GELS's competition here
Lannett Company, Inc. (NYSE: LCI)
GRVI vs LCI Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas LCI's P/E ratio is -0.04. In terms of profitability, GRVI's ROE is -2.54%, compared to LCI's ROE of +1.66%. Regarding short-term risk, GRVI is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
GRVI vs ADMP Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ADMP's P/E ratio is -0.08. In terms of profitability, GRVI's ROE is -2.54%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, GRVI is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
GRVI vs YCBD Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, YCBD has a market cap of 5M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while YCBD trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas YCBD's P/E ratio is -1.17. In terms of profitability, GRVI's ROE is -2.54%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, GRVI is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check YCBD's competition here
Mallinckrodt plc (AMEX: MNK)
GRVI vs MNK Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas MNK's P/E ratio is -0.44. In terms of profitability, GRVI's ROE is -2.54%, compared to MNK's ROE of -0.36%. Regarding short-term risk, GRVI is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
GRVI vs FLGC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas FLGC's P/E ratio is -0.19. In terms of profitability, GRVI's ROE is -2.54%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, GRVI is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
GRVI vs UPC Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, UPC has a market cap of 2.7M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while UPC trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas UPC's P/E ratio is -0.54. In terms of profitability, GRVI's ROE is -2.54%, compared to UPC's ROE of -0.03%. Regarding short-term risk, GRVI is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
GRVI vs SBFM Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, SBFM has a market cap of 2.6M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while SBFM trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas SBFM's P/E ratio is -0.18. In terms of profitability, GRVI's ROE is -2.54%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, GRVI is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
GRVI vs PLXP Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas PLXP's P/E ratio is -0.22. In terms of profitability, GRVI's ROE is -2.54%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, GRVI is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
GRVI vs ATNX Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas ATNX's P/E ratio is -0.02. In terms of profitability, GRVI's ROE is -2.54%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, GRVI is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check ATNX's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
GRVI vs RDHL Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, RDHL has a market cap of 2.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while RDHL trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas RDHL's P/E ratio is 0.14. In terms of profitability, GRVI's ROE is -2.54%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, GRVI is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for GRVI.Check RDHL's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
GRVI vs SNOA Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while SNOA trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas SNOA's P/E ratio is -1.12. In terms of profitability, GRVI's ROE is -2.54%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, GRVI is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
GRVI vs SHPH Comparison September 2026
Upexi, Inc. (NASDAQ: GRVI) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRVI stands at 88.9M. In comparison, SHPH has a market cap of 2M. Regarding current trading prices, GRVI is priced at $4.95 on the NASDAQ, while SHPH trades at $3.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRVI currently has a P/E ratio of 26.05, whereas SHPH's P/E ratio is -0.16. In terms of profitability, GRVI's ROE is -2.54%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, GRVI is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for GRVI.Check SHPH's competition here